BRIEF-Adamas Pharmaceuticals' ease lid 2 trial is ongoing, and patients are being followed for up to two years
October 27, 2016 at 08:29 AM EDT
* Adamas submits new drug application to u.s. Fda for ads-5102 for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease
